State Street
BCAX

State Street’s Bicara Therapeutics BCAX Stock Holding History

State Street’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.2M Sell
1,419,388
-230,149
-14% -$3.96M ﹤0.01% 2052
2025
Q4 		$27.8M Buy
1,649,537
+1,059,260
+179% +$18.1M ﹤0.01% 2073
2025
Q3 		$9.32M Buy
590,277
+49,210
+9% +$551K ﹤0.01% 2678
2025
Q2 		$5.03M Buy
541,067
+170,936
+46% +$2.04M ﹤0.01% 2941
2025
Q1 		$4.82M Buy
370,131
+65,400
+21% +$868K ﹤0.01% 2899
2024
Q4 		$5.31M Buy
+304,731
New +$6.34M ﹤0.01% 2944

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

State Street's BCAX Position: Q1 2026 in Review

State Street reduced its Bicara Therapeutics (BCAX) stake by 14% in Q1 2026, selling an estimated $3.96M and leaving 1,419,388 shares worth $28.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2052.

State Street first reported a position in BCAX in Q4 2024 and has held it in 6 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • State Street held 1,419,388 shares of Bicara Therapeutics worth $28.2M as of Q1 2026.
  • State Street sold 230,149 Bicara Therapeutics shares in Q1 2026, an estimated $3.96M.
  • Bicara Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #2052 holding.
  • State Street first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.